Nour E A Abd El-Sattar (Nour El-Din Ahmed Abd El-Sattar)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Candida Albicans

Vascular Endothelial Growth Factor

Breast Cancer Cells

Papillary Thyroid

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Mohamady Ghobashy, Ghada Bassioni, Ahmed Zaher, H Abd El-Wahab, Norhan Nady, Amira El-Sayed, Amr Osman, Nour E A Abd El-Sattar
Radiation Synthesis of Carbon/Aluminum/Silica Aerogel Nanoporous Structure Derived from Polyacrylamide Hydrogel for High Temperature and Oil Removal Applications. ACS omega 8 (23) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Kurls E Anwer, Sanadelaslam S A El-Hddad, Nour E A Abd El-Sattar, Ahmed El-Morsy, Fathalla Khedr, Samy Mohamady, Doaa E Keshek, Samir A Salama, Khaled El-Adl, Noura S Hanafy
Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR T790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations. RSC advances 13 (50) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Samia M Al-Muntaser, Ahmed Ali Al-Karmalawy, Abeer M El-Naggar, Ali Khalil Ali, Nour E A Abd El-Sattar, Eslam M Abbass
Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC advances 13 (18) (2023)
Kurls E Anwer, Nour E A Abd El-Sattar, Marium M Shamaa, Mohamed Y Zakaria, Botros Y Beshay
Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability. Pharmaceuticals (Basel, Switzerland) 15 (3) (2022)
Mohamed Abdelwahab Abdelgawad, Khaled El-Adl, Sanadelaslam S A El-Hddad, Mostafa M Elhady, Nashwa M Saleh, Mohamed M Khalifa, Fathalla Khedr, Mohamed Alswah, AbdEIAziz A Nayl, Mohammed M Ghoneim, Nour E A Abd El-Sattar
Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Pharmaceuticals (Basel, Switzerland) 15 (2) (2022)
Nour E A Abd El-Sattar, Eman H K Badawy, Eman Z Elrazaz, Nasser S M Ismail
Discovery of pyrano[2,3- d ]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity. RSC advances 11 (8) (2021)